Loading patent…
AssigneeGdanski Uniwersytet Medyczny
InventorsMarcin Okroj, Anna Felberg-Mietka, Aleksandra Urban
Estimating the term…
The subject of this invention is point mutants of human proteins constituting the complement system's C3 and C5 convertases, where the mutation are as follows: For the factor B: —D279G, F286L, K323E, Y363A; D279G_F286L_K323E_Y363A—quadruple mutant; For the C2 protein: —C261A, Q.263G, Y347A, L348A; T442Q, double mutants C261A_Q263G and Y347A_Q263G, triple mutant Y347A_Q263G_T442Q The subject of this invention is the method of enhancing the activity of the anti-cancer antibodies, which includes the addition of mutants defined above. The subject of this invention is the pharmaceutical composition, which includes the therapeutically effective number of mutants defined above. The subject of this invention is the use of mutants defined above to enhance the cytotoxic activity of anti-cancer antibodies in therapy and in the treatment of neoplastic diseases.
A composition comprising a mutant Factor B protein, wherein the mutant Factor B protein is a Factor B protein with D279G, F286L, K323E, and Y363A mutations, wherein the mutations are relative to the Factor B protein of SEQ ID NO.:1 and
A composition comprising a mutant C2 protein, wherein the mutant C2 protein is selected from the group consisting of:
Dependencies are inferred from the claim text.